Latest News and Press Releases
Want to stay updated on the latest news?
-
LEIDEN, The Netherlands, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for...
-
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet...
-
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet...
-
Rolling NDA submission drisapersen underway EMA filing for conditional approval anticipated to follow NDA submission Re-dosing has commenced in United States, Belgium &...
-
Leiden, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Monday,...
-
Leiden, The Netherlands, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans Schikan, Chief Executive Officer, will present a corporate overview at the...
-
Leiden, The Netherlands, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet...
-
Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy
Leiden, The Netherlands, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet...
-
Leiden, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans Schikan, Chief Executive Officer, will present a corporate overview at the...
-
Leiden, The Netherlands, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet...